All Posts By

CND Life Sciences

Researchers Identify Five Genes Linked to Lewy Body Dementia

By In the News

By identifying potential genetic causes of Lewy body dementia (LBD), researchers hope to gain a better understanding of the devastating neurodegenerative disorder, for which there are no treatments. It is already known that LBD, Parkinson’s disease (PD), and Alzheimer’s disease (AD) are all caused by clumps of proteins that build up in the nerve cells of the brain (alpha-synuclein in LBD and PD, tau in AD). The three diseases have some overlapping symptoms and related features of neurodegeneration.

Read More

New Research Furthers Understanding of the Role of Alpha-Synuclein, a Key Protein in Parkinson’s Disease

By In the News

Although some symptoms of Parkinson’s disease (PD) can be controlled by medication, the hope of researchers, patients, and clinicians is that we can discover a treatment that can stop or reverse the course of PD and eventually find a cure. Central to developing disease-modifying treatments is an understanding of the role of alpha-synuclein, a key protein found in everyone’s brain, that’s recognized as a cause of PD.

Read More

Researchers Identify Proteins With Potential to Treat Parkinson’s Disease

By In the News

Parkinson’s is a complicated neurological disorder that researchers are continuously working to understand. However, a lack of dopamine—a neurotransmitter responsible for our ability to control the way our bodies move (among many other things)—is widely recognized as a cause.

Recently, a team of researchers based in Israel evaluated whether certain proteins, known as bone morphogenetic proteins 5 and 7 (BMP5/7), could protect dopamine-producing neurons in the brains of mice from damage caused by the misfolded alpha-synuclein protein, another major player in the cause of Parkinson’s disease.

The researchers found that not only did BMP5/7 reverse the alpha-synuclein-induced loss of dopamine-producing neurons, but it also reduced the accumulation of alpha-synuclein in the brain and prevented motor impairment in the study mice. The authors conclude that BMPs are a promising option in the development of disease-modifying treatments for Parkinson’s, an area of significant unmet need.

Read More

Dr. Todd Levine Talks With Medical World News About the Potential of the Syn-One Test™ to Impact Patients’ Care

By In the News

Todd Levine, MD, Co-Founder and Chief Medical Officer of CND Life Sciences was recently interviewed on Medical World News about the development of the Syn-One Test, how it can lead to better clinical decision making, and its potential to significantly impact the lives of patients with Parkinson’s disease, dementia with Lewy bodies, pure autonomic failure, and multiple system atrophy.

Read More